Connor, Clark & Lunn Investment Management (CC&L)
ZYNE

Connor, Clark & Lunn Investment Management (CC&L)’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-34,371
Closed -$146K – 1244
2021
Q3 		$146K Buy
+34,371
New +$153K ﹤0.01% 966

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ZYNE Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2021, closing a stake of 34,371 shares — an estimated $146K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ZYNE in Q3 2021 and held it in 1 quarter. The position peaked at $146K in Q3 2021. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 34,371 Zynerba Pharmaceuticals, Inc shares in Q4 2021, an estimated $146K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2021 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Zynerba Pharmaceuticals, Inc position peaked at $146K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.